sales and revenue examples, page-9

Zogenix, Inc. (ZGNX: Quote) said Friday that the U.S. Food and Drug Administration's Anesthetic and Analgesic Drug Products Advisory Committee voted 2-11, with 1 abstention, against the approval of Zohydro ER, an extended-release formulation of hydrocodone without acetaminophen, for the management of moderate-to-severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

http://www.rttnews.com/2020020/fda-panel-rejects-zogenix-s-pure-hydrocodone-painkiller-zohydro-er.aspx?type=fdp

Not the end of the line for them but a good indication of sentiment toward ERIC opioids without abuse deterrents. Not the case for MoxDuo CR.